174 related articles for article (PubMed ID: 31882734)
21. High performance of targeted next generation sequencing on variance detection in clinical tumor specimens in comparison with current conventional methods.
Su D; Zhang D; Chen K; Lu J; Wu J; Cao X; Ying L; Jin Q; Ye Y; Xie Z; Xiong L; Mao W; Li F
J Exp Clin Cancer Res; 2017 Sep; 36(1):121. PubMed ID: 28882180
[TBL] [Abstract][Full Text] [Related]
22. Molecular profiling of 6,892 colorectal cancer samples suggests different possible treatment options specific to metastatic sites.
El-Deiry WS; Vijayvergia N; Xiu J; Scicchitano A; Lim B; Yee NS; Harvey HA; Gatalica Z; Reddy S
Cancer Biol Ther; 2015; 16(12):1726-37. PubMed ID: 26553611
[TBL] [Abstract][Full Text] [Related]
23. Next generation sequencing in cancer: opportunities and challenges for precision cancer medicine.
Paolillo C; Londin E; Fortina P
Scand J Clin Lab Invest Suppl; 2016; 245():S84-91. PubMed ID: 27542004
[TBL] [Abstract][Full Text] [Related]
24. The long tail of molecular alterations in non-small cell lung cancer: a single-institution experience of next-generation sequencing in clinical molecular diagnostics.
Fumagalli C; Vacirca D; Rappa A; Passaro A; Guarize J; Rafaniello Raviele P; de Marinis F; Spaggiari L; Casadio C; Viale G; Barberis M; Guerini-Rocco E
J Clin Pathol; 2018 Sep; 71(9):767-773. PubMed ID: 29535211
[TBL] [Abstract][Full Text] [Related]
25. Utility of comprehensive genomic sequencing for detecting HER2-positive colorectal cancer.
Shimada Y; Yagi R; Kameyama H; Nagahashi M; Ichikawa H; Tajima Y; Okamura T; Nakano M; Nakano M; Sato Y; Matsuzawa T; Sakata J; Kobayashi T; Nogami H; Maruyama S; Takii Y; Kawasaki T; Homma KI; Izutsu H; Kodama K; Ring JE; Protopopov A; Lyle S; Okuda S; Akazawa K; Wakai T
Hum Pathol; 2017 Aug; 66():1-9. PubMed ID: 28235632
[TBL] [Abstract][Full Text] [Related]
26. Responses to crizotinib in patients with ALK-positive lung adenocarcinoma who tested immunohistochemistry (IHC)-positive and fluorescence in situ hybridization (FISH)-negative.
Ma D; Wang Z; Yang L; Mu X; Wang Y; Zhao X; Li J; Lin D
Oncotarget; 2016 Sep; 7(39):64410-64420. PubMed ID: 27418132
[TBL] [Abstract][Full Text] [Related]
27. Precision oncology based on omics data: The NCT Heidelberg experience.
Horak P; Klink B; Heining C; Gröschel S; Hutter B; Fröhlich M; Uhrig S; Hübschmann D; Schlesner M; Eils R; Richter D; Pfütze K; Geörg C; Meißburger B; Wolf S; Schulz A; Penzel R; Herpel E; Kirchner M; Lier A; Endris V; Singer S; Schirmacher P; Weichert W; Stenzinger A; Schlenk RF; Schröck E; Brors B; von Kalle C; Glimm H; Fröhling S
Int J Cancer; 2017 Sep; 141(5):877-886. PubMed ID: 28597939
[TBL] [Abstract][Full Text] [Related]
28. Interim analysis of a real-world precision medicine platform for molecular profiling of metastatic or advanced cancers: MONDTI.
Kieler M; Unseld M; Bianconi D; Waneck F; Mader R; Wrba F; Fuereder T; Marosi C; Raderer M; Staber P; Berger W; Sibilia M; Polterauer S; Müllauer L; Preusser M; Zielinski CC; Prager GW
ESMO Open; 2019; 4(4):e000538. PubMed ID: 31423337
[TBL] [Abstract][Full Text] [Related]
29. Clinical Trial Considerations in Neuro-oncology.
Lee EQ
Curr Treat Options Oncol; 2021 Jul; 22(9):78. PubMed ID: 34213625
[TBL] [Abstract][Full Text] [Related]
30. Precision Medicine for the Management of Therapy Refractory Colorectal Cancer.
Taghizadeh H; Mader RM; Müllauer L; Erhart F; Kautzky-Willer A; Prager GW
J Pers Med; 2020 Dec; 10(4):. PubMed ID: 33322358
[TBL] [Abstract][Full Text] [Related]
31. Exploring sialyl-Tn expression in microfluidic-isolated circulating tumour cells: A novel biomarker and an analytical tool for precision oncology applications.
Neves M; Azevedo R; Lima L; Oliveira MI; Peixoto A; Ferreira D; Soares J; Fernandes E; Gaiteiro C; Palmeira C; Cotton S; Mereiter S; Campos D; Afonso LP; Ribeiro R; Fraga A; Tavares A; Mansinho H; Monteiro E; Videira PA; Freitas PP; Reis CA; Santos LL; Dieguez L; Ferreira JA
N Biotechnol; 2019 Mar; 49():77-87. PubMed ID: 30273682
[TBL] [Abstract][Full Text] [Related]
32. Precision medicine in breast cancer.
Naito Y; Urasaki T
Chin Clin Oncol; 2018 Jun; 7(3):29. PubMed ID: 30056731
[TBL] [Abstract][Full Text] [Related]
33. Molecular diagnostic characteristics based on the next generation sequencing in lung cancer and its relationship with the expression of PD-L1.
Liu J; Liu Y
Pathol Res Pract; 2020 Feb; 216(2):152797. PubMed ID: 31926773
[TBL] [Abstract][Full Text] [Related]
34. The role of tumor board conferences in neuro-oncology: a nationwide provider survey.
Snyder J; Schultz L; Walbert T
J Neurooncol; 2017 May; 133(1):1-7. PubMed ID: 28421461
[TBL] [Abstract][Full Text] [Related]
35. Doing more with less: fluorescence in situ hybridization and gene sequencing assays can be reliably performed on archival stained tumor tissue sections.
Pelosi G; Perrone F; Tamborini E; Fabbri A; Testi MA; Busico A; Settanni G; Picciani B; Bovio E; Sonzogni A; Valeri B; Garassino M; De Braud F; Pastorino U
Virchows Arch; 2016 Apr; 468(4):451-61. PubMed ID: 26818831
[TBL] [Abstract][Full Text] [Related]
36. Neuro-Oncology.
Batchelor T; Wick W
Semin Neurol; 2018 Feb; 38(1):3-4. PubMed ID: 29548045
[No Abstract] [Full Text] [Related]
37. Delivering on the promise of precision cancer medicine.
Berger MF; Van Allen EM
Genome Med; 2016 Oct; 8(1):110. PubMed ID: 27782852
[No Abstract] [Full Text] [Related]
38. Precision oncology: East meets West.
Subbiah V; Rodon J; Yap TA
Int J Cancer; 2018 May; 142(9):1734-1737. PubMed ID: 29243227
[No Abstract] [Full Text] [Related]
39. Molecular characterization of EGFR and EGFR-downstream pathways in triple negative breast carcinomas with basal like features.
Martin V; Botta F; Zanellato E; Molinari F; Crippa S; Mazzucchelli L; Frattini M
Histol Histopathol; 2012 Jun; 27(6):785-92. PubMed ID: 22473698
[TBL] [Abstract][Full Text] [Related]
40. Definitions and statistical properties of master protocols for personalized medicine in oncology.
Renfro LA; Mandrekar SJ
J Biopharm Stat; 2018; 28(2):217-228. PubMed ID: 28877008
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
